Video

Dr. Batlevi on Emerging Therapies in Follicular Lymphoma

Author(s):

Connie Batlevi, MD

Connie L. Batlevi, MD, PhD, discusses emerging therapies in follicular lymphoma.

Connie L. Batlevi, MD, PhD, a medical oncologist specializing in lymphoma at Memorial Sloan Kettering Cancer Center, discusses emerging therapies in follicular lymphoma.

​Several emerging therapies ​in the follicular lymphoma pipeline ​have shown encouraging data, says Batlevi.

Strategies based on modulating immune response have comprised a significant area of research, ​Batlevi explains. Additionally, the utility of CAR T-cell therapy, antibody​-drug conjugates, and bispecific antibodies ​is also being evaluated.

​Future research efforts should focus on identifying an optimal sequencing method ​for patients with follicular lymphoma, especially as more options are introduced to the armamentarium, Batlevi concludes. 

Related Videos
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD
Related Content
Nausheen Ahmed, MD, MBBS
July 24th 2024

Reduced Incidence of ICANS and CRS After 2 Weeks Post-CAR T Supports Shortened Monitoring Period in DLBCL

Matthew Lunning, DO, FACP
December 21st 2023

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

Brentuximab Vedotin Triplet in R/R DLBCL Subgroups | Image Credit: © freshidea - stock.adobe.com
July 17th 2024

Brentuximab Vedotin Triplet Improves Survival Over R2 Across Key R/R DLBCL Subgroups

Matthew Lunning, DO, FACP
October 30th 2023

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

Francisco Hernandez-Ilizaliturri, MD
July 15th 2024

CAR T-Cell Therapy Selection in Follicular Lymphoma Requires Careful Consideration

Grzegorz S. Nowakowski, MD, of Mayo Clinic
July 12th 2024

Epcoritamab Shines in Third-Line Follicular Lymphoma With the Potential to Move into Earlier Lines